ABSTRACT OF THE DISCLOSURE

This invention pertains to pharmaceutical formulations which comprise (i) a drug (e.g., an amphiphilic drug) (e.g., an anthracycline) (e.g., doxorubicin) and (ii) a short-chain sphingolipid (e.g., a short-chain glycosphingolipid or a short-chain sphingomyelin) (e.g., N-octanoyl-glucosylceramide, referred to as C_8 -GlcCer) (e.g., N-hexanoyl-sphingomyelin, referred to herein as C_8 -SM), and which provide improved drug delivery and efficacy. The short-chain sphingolipidis selected from compounds of the following formula:

$$\begin{array}{c|c}
R^{N} & O \\
R^{1} & R^{2} \\
R^{4} & R^{5}
\end{array}$$

wherein: R1 is independently: an O-linked saccharide group; or an O-linked polyhydric alcohol group; or: R1 is independently: an O-linked (optionally N-(C1-4alkyl)-substituted amino)-C1-6alkylphosphate group; or an O-linked (polyhydric alcohol-substituted)-C₁₋₆alkyl-phosphate group; R² is independently C₃₋₉alkyl, and is independently unsubstituted or substituted; R³ is independently C₇₋₁₉alkyl, and is independently unsubstituted or substituted; R⁴ is independently -H, -OH, or -O-C₁₄alkyl; R^N is independently -H or C₁₄alkyl; the bond marked with an alpha (α) is independently a single bond or a double bond; if the bond marked with an alpha (α) is a double bond, then R^5 is -H; if the bond marked with an alpha (α) is a single bond, then R^5 is -H or -OH; the carbon atom marked (*) is independently in an R-configuration or an S-configuration; the carbon atom marked (**) is independently in an R-configuration or an S-configuration; and pharmaceutically acceptable salts, solvates, esters, ethers, chemically protected forms thereof. In one embodiment, the pharmaceutical formulation is a liposomal pharmaceutical formulation prepared using a mixture of lipids comprising, at least, vesicle-forming lipids (e.g., phospholipids) (e.g., phosphatidylcholines) (e.g., fully hydrogenated soy phosphatidylcholine (HSPC)) (e.g., dipalmitoyl-phosphatidylcholine (DPPC)) and said short-chain sphingolipid, and optionally cholesterol and optionally a vesicle-forming lipid which is derivatized with a polymer chain (e.g., a phosphatidylethanolamine (PE) which is derivatized with polyethyleneglycol (PEG)) (e.g., N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3phosphoethanolamine sodium salt (MPEG2000-DSPE). The present invention also pertains to methods for the preparation and use of such formulations.